Lorlatinib for ALK‐fused, infant‐type hemispheric glioma with lung metastasis: a case report

Infant‐type hemispheric glioma, a new subtype of pediatric high‐grade glioma, arises in the cerebral hemispheres. Despite better survival outcomes, the treatment of infant‐type hemispheric glioma is still facing challenges. Here, we reported a case of QKI‐ALK fusion, infant‐type hemispheric glioma w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Mingyao, Li, Shaoqun, Li, Hainan, Hu, Qingjun, Li, Juan, Zhou, Jiangfen, Ai, Ruyu, Zhen, Junjie, Zhou, Zhaoming, Wang, Lichao, Zhang, Yangqiong, Hu, Wanming, Yuan, Li, Ma, Xuejiao, Zhang, Xing, Song, Chao, Li, Zhi, Cai, Linbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187722/
https://www.ncbi.nlm.nih.gov/pubmed/37000961
http://dx.doi.org/10.1002/acn3.51766
Descripción
Sumario:Infant‐type hemispheric glioma, a new subtype of pediatric high‐grade glioma, arises in the cerebral hemispheres. Despite better survival outcomes, the treatment of infant‐type hemispheric glioma is still facing challenges. Here, we reported a case of QKI‐ALK fusion, infant‐type hemispheric glioma with lung metastasis who achieved a complete clinical response after lorlatinib treatment. This typical case demonstrated the importance of appropriate molecularly targeted treatments in ALK‐fused tumors, and lorlatinib may serve as an effective complement to conventional chemotherapy and radiotherapy in primary glioma harboring ALK fusions and its metastasis.

Ejemplares similares